Business diary for week of April 29

April 28, 2013

Short takes on the week's announcements and deals.

Awards

Fairfax-based Women in Technology has named the winners of its 14th annual Leadership Awards: Private Sector Large Business — Elaine Anderson of Computer Sciences Corp.; Private Sector Small Business — Mary Knebel Gillespie of Alarm.com; Public Sector Large Business — Julie Taylor of Science Applications International Corp.; Public Sector Small Business — Angie Lienert of Intelligenesis; Entrepreneur — Dawn Halfaker of Halfaker and Associates; Government — Lorraine Landfried of the Department of Veteran Affairs; Health IT — Stephanie Pincus of the National Academies of Science; Rising Star — Marlene Roush of SAIC and Stacy Tedesco of the D.C. Public Schools; Social Impact IT — Donna Rice Hughes of Enough is Enough; Unsung Hero — Nora Robertson of Navy ERP; WIT Champion — Kelly Moore of AT&T; President’s Award — Colleen Oresky, chairwoman of WIT sponsor committee and Deb Hennessy, chairwoman of WIT Share Our Success events; and Founders Award — Nanci Schimizzi of the Financial Industry Regulatory Authority.

Expansions

Tysons Corner-based dog day care company Dogtopia said it has signed a regional developer agreement for the Orange County area in California, with plans to open 13 locations there.

Moves

Information and data management company IQ Business Group said it has moved its headquarters from Atlanta to 1410 Spring Hill Rd., Fourth Floor, McLean, VA 22102.

Technology and consulting company GP Strategies said it will move its headquarters from Elkridge to 70 Corporate Center, 11000 Broken Land Pkwy., Columbia, MD 21044.

Pharmaceuticals

Bethesda-based Sucampo Pharmaceuticals said that it has received approval from the Food and Drug Administration for its Amitiza drug to be used for the treatment of opioid-induced constipation.

Rockville-based Neuralstem said it has received approval from the Food and Drug Administration to begin dosing the third and final cohort of patients in its ongoing Phase Ib trial to test the safety of its NSI-189 in the treatment of major depressive disorder.

— Compiled by Shawn Selby

Continue reading
Comments
Show Comments
Most Read Business

business

capitalbusiness

Success! Check your inbox for details.

See all newsletters